Preclinical Studies

Australis Pharma maintains a healthy pipeline of lead compound and chemical entities in various stages of R&D and preclinical testing.

AUS_001 for Pancreatic Cancer [expected to enter the clinic in 2022]
AUS_001 for glioblastoma [expected to enter the clinic in 2022]
AUS_001 for Brain Metastases [expected to enter the clinic 2022]
AUS_119 is in preclinical development with established in vitro and in vivo efficacy against Kidney, Pancreatic, and Lung cancer.
AUS_143 is in preclinical development with established in vitro efficacy.
AUS_146 is in preclinical development with established in vitro efficacy.

Australis Pharma has partnered with institutions around the world to substantiate its groundbreaking findings. The lead candidate AUS_001 is in the late preclinical stage and has garnered a lot of attention for its stellar in vitro and in vivo findings. Specifically:

High potency on wide range of cancers with efficacy on 273 of 280 types of cancer cell lines and 20-40x safety margin.
No side effects of traditional chemotherapy yet selective for cancer cells (LD50 PO exceeds 2000 mg/kg)
Leading Global CRO: “Strongest performing compound ever” in OncoPanel screening
Eradicates 98% of tumors after 3 Weeks of treatment, and stunts all tumor growth in mouse model.
Natural origin via Kangaroo Island bees yet demonstrates superior safety, efficacy, and delivery compared to other chemotherapies